[Cardiovascular disease in HIV-infected patients on highly active antiretroviral therapy]. 2004

Carlos Jericó, and Hernando Knobel, and Alexia Carmona, and M Luisa Sorli, and José Luis López-Colomés, and Juan Pedro-Botet
Servicio de Medicina Interna-Enfermedades Infecciosas, Hospital del Mar, Universidad Autónoma de Barcelona, Spain.

OBJECTIVE Our goal was to assess the main characteristics of cardiovascular disease in HIV-infected patients on highly active antiretroviral therapy (HAART). METHODS Retrospective analysis of the clinico-epidemiological characteristics of 16 HIV-infected patients treated with HAART who had suffered a cardiovascular event from a 1,459 patients' cohort. RESULTS Clinical presentation of cardiovascular disease was an acute coronary syndrome in 12 cases, ischemic stroke in 2 and peripheral vascular disease in 2. Patients included in the study had a mean of 3.2 cardiovascular risk factors, smoking and low HDL levels being the more prevalent risk factors. Eight (50%, 95% CI, 25-75%) patients fulfilled the criteria of metabolic syndrome. The mean CD4 count was 548 x 10(6)/l. CONCLUSIONS HIV-infected patients on HAART ha-ve a high cardiovascular risk. A strict management of modifiable risk factors must be warranted in these patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Carlos Jericó, and Hernando Knobel, and Alexia Carmona, and M Luisa Sorli, and José Luis López-Colomés, and Juan Pedro-Botet
January 2003, Current pharmaceutical design,
Carlos Jericó, and Hernando Knobel, and Alexia Carmona, and M Luisa Sorli, and José Luis López-Colomés, and Juan Pedro-Botet
August 2009, Neurology,
Carlos Jericó, and Hernando Knobel, and Alexia Carmona, and M Luisa Sorli, and José Luis López-Colomés, and Juan Pedro-Botet
May 2013, Nigerian medical journal : journal of the Nigeria Medical Association,
Carlos Jericó, and Hernando Knobel, and Alexia Carmona, and M Luisa Sorli, and José Luis López-Colomés, and Juan Pedro-Botet
August 2010, The Journal of clinical endocrinology and metabolism,
Carlos Jericó, and Hernando Knobel, and Alexia Carmona, and M Luisa Sorli, and José Luis López-Colomés, and Juan Pedro-Botet
July 2008, Circulation,
Carlos Jericó, and Hernando Knobel, and Alexia Carmona, and M Luisa Sorli, and José Luis López-Colomés, and Juan Pedro-Botet
January 2002, Journal of acquired immune deficiency syndromes (1999),
Carlos Jericó, and Hernando Knobel, and Alexia Carmona, and M Luisa Sorli, and José Luis López-Colomés, and Juan Pedro-Botet
November 2007, Journal of gastroenterology and hepatology,
Carlos Jericó, and Hernando Knobel, and Alexia Carmona, and M Luisa Sorli, and José Luis López-Colomés, and Juan Pedro-Botet
October 2002, International journal of STD & AIDS,
Carlos Jericó, and Hernando Knobel, and Alexia Carmona, and M Luisa Sorli, and José Luis López-Colomés, and Juan Pedro-Botet
February 2017, Acta clinica Belgica,
Carlos Jericó, and Hernando Knobel, and Alexia Carmona, and M Luisa Sorli, and José Luis López-Colomés, and Juan Pedro-Botet
January 2005, Antiviral therapy,
Copied contents to your clipboard!